Track record
Experience measured in programs advanced and filings approved.
- A dozen
- IND filings supported in the US and Europe
- ~1,000
- discovery studies managed per year at Sanofi/Genzyme, with a 5-day request-to-report turnaround
- >90%
- time saved on discovery PK study management, reporting, and sample preparation through automation
- 10+ · 10+
- years representing a CRO, and years representing a sponsor
NDA approvals supported
- Mozobil® (plerixafor injection)
- Clolar® (clofarabine)
- Cerdelga® (eliglustat)
- Aubagio® (teriflunomide)
Approved across the US, Europe, Japan, Canada, and Australia.
IND programs supported
- Venglustat (GZ/SAR402671)
- GZ389988
Plus dozens of discovery programs from lead optimization to candidate nomination in rare disease, CNS, oncology, and lung disease.
Program experience from Dr. Ho's tenure at Sanofi/Genzyme. Product names are trademarks of their respective owners.
Recognition
- 2023Best Poster Award (two awards), CICoR Science DayChina Innovation Center of Roche (CICoR): “Single-Dose PK (SDPK) Data Uploading, Analysis and Presentation via Digital Automation” and “Prediction of Thermodynamic Solubility Using Conditional Graph Neural Network (GNN)”
- 2023Simplify Radically Award, CICoR Science DayFor developing and implementing the Certificate of Testing (COT) system for tracking and testing test articles and analytical reference materials
- 2016Publication – Operational Excellence, Boston R&D Science AwardsSanofi, for “Surrogate matrix: opportunities and challenges for tissue sample analysis”
- 2015Publication – Operational Excellence; We R Hope – Innovative Therapeutic ApproachSanofi Boston R&D Science Awards
Workflow modernization
Modernize the workflow, not just the data.
ARTI helps teams adopt automation, structured reporting, and model-informed drug development (MIDD) without losing productivity, with experimental validation remaining the decision gate.
At Roche, Dr. Ho streamlined single-dose PK and material-transfer workflows with the AI, Data and Digital group, improving operating efficiency by more than 90%, and co-developed machine-learning models for single-dose PK, microsomal stability, and thermodynamic solubility that outperformed commercial prediction software.